Signs of her2 negative breast neoplasms are present at presentation and can include a palpable lump, nipple discharge, lumps on other body sites and enlargement of the axillary lymph nodes.\n
Her2/neu loss-of-action and overexpression are not rare events leading to breast cancer. HER2/neu can be overexpressed in tumors of women with no known genetic susceptibility to Her2/neu, or it can be shed from the tumor of women with a her2 mutation but no somatic EGFR gene amplification. Tumor proteins, such as p63 or MUC-1, inactivation of the Her2/neu receptor, may contribute to tumorigenesis. Data from a recent study underscore the need for improved diagnostic approaches in diagnosing and treating patients with breast cancer.
In the era of hormonal blockage therapy and targeted therapy, patients with HER2 negative breast cancers should be discussed with a multidisciplinary expert, and a discussion should include treatment options.
Around 32,000 people in the US get a her2 negative breast neoplasm annually. Around 40% of those with HER2 amplification require trastuzumab for disease treatment.
Data from a recent study are not yet convincing enough to prove the existence of a cure for her2-positive [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). However, our data shows a possible improvement with time. Thus, new, larger clinical trials are justified to determine if there is at the moment a cure for patients with her2-positive breast-cancer. Future trials are also warranted in patients negative for ER.
HER2 expression is often present in ductal carcinomas in situ and it is common in invasive [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer)s. HER2 expression is also present in a subset of breast tumors that share a profile with some triple negative breast cancers.
Her2 overexpression is associated with aggressive disease behavior and poor outcome in breast carcinomas. This overexpression of the ER-alpha and/or c-HER2 genes can be evaluated by utilizing the FDA-approved Herceptin(trastuzumab). It appears that the clinical significance of the Herceptin-positive Her2-negative breast tumors has been underestimated. This is evidenced through the poorer outcome of the patients treated with Herceptin versus patients treated with Herceptin-containing regimens.
SGN-B7h4v as an anti HER2 monoclonal antibody demonstrated a significant improvement in tumor-free and overall survival. Therefore, SGN-B7h4v is highly recommended for the treatment of HER2-negative recurrent breast cancer regardless of their expression of HER2.
Her2 negative breast cancer development may be multifactorial. The most common causes of her2 negative breast cancer appear to be the local environment, tumor microfiltrating lymphocytes, HER2 gene and the presence of a family history of breast cancer.
Sgn-b7h4v, administrated intravenously at a dose of 4.5 mg, caused no detectable side-effects in the first 30 days of the treatment, and no clinical symptoms of systemic side-effect were observed in both patients and controls. Sgn-b7h4v is a promising new medication for the treatment of patients with advanced breast cancer.
SGN-b7h4v is a new antibody conjugated to the VH3 domain derived from the SGN VH3 domain. It is an antibody that has shown potent growth and proliferation inhibition activity against tumor cell lines in both in vitro and in vivo studies. Further studies are needed to determine the applicability of sgn-b7h4v in breast cancer patients for the therapeutic utility.
In a recent study, findings identified the common side effects of sgn-b7h4v, which include fatigue, weight loss, nausea, cough, and diarrhea. Based on these side effects, clinicians should monitor the side effects during the treatment of SGN-P1 patients.